Relationship of Cancer to Brain Aging Markers of Alzheimer’s Disease: The Framingham Heart Study-Advances in Geriatric Medicine and Research-CSCIED科技核心评价数据库-手机版

Relationship of Cancer to Brain Aging Markers of Alzheimer’s Disease: The Framingham Heart Study

Relationship of Cancer to Brain Aging Markers of Alzheimer’s Disease: The Framingham Heart Study

ES评分 0 浏览量：818 下载量：0

DOI	10.20900/agmr20190006
刊名	Advances in Geriatric Medicine and Research AGMR
年，卷(期)	2019, 1(1)
作者	Apar Gupta,Sarah R. Preis,Alexa S. Beiser,Greta L. Splansky,Charles S. DeCarli,Rhoda Au,Jane A. Driver*,
作者单位	1 Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ 08903, USA; 2 Framingham Heart Study, Boston University School of Medicine, Framingham, MA 01702, USA; 3 Department of Biostatistics, Boston University School of Public Health, Boston, MA 02118, USA; 4 Department of Neurology, Boston University School of Medicine, Boston, MA 02118, USA; 5 Center for Neuroscience, Department of Neurology, University of California-Davis, Sacramento, CA 95817, USA; 6 Department of Anatomy & Neurobiology, Boston University School of Medicine, Boston, MA 02118, USA; 7 Department of Epidemiology, Boston University School of Public Health, Boston, MA 02118, USA; 8 New England Geriatric Research Education and Clinical Center, VA Boston Healthcare System, Boston, MA 02130, USA; 9 Division of Aging, Department of Medicine, Brigham and Women’s Hospital, Boston, MA 02120, USA; 10 Division of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
Abstract	Background: Previous studies have demonstrated a strong inverse association between cancer and risk of Alzheimer’s disease (AD). This study aimed to further investigate this association by examining measures of cognitive performance and neuroimaging.Methods: Neuropsychological (NP) test batteries consisting of quantitative measures of memory and executive function and volumetric brain magnetic resonance imaging (MRI) scans measuring brain and white-matter hyperintensity volumes were administered to 2043 dementia-free participants (54% women) in the Framingham Heart Study (FHS) Offspring cohort from 1999 to 2005. History of cancer was assessed at examination visits and through hospital records. Linear regression was used to examine the association between cancer history and NP/MRI variables.Results: There were 252 and 1791 participants with and without a previous history of cancer, respectively. Cancer survivors had an average time between diagnosis and NP/MRI exam of 9.8 years. History of any invasive cancer was associated with better executive function (Beta = 0.16, p = 0.04) but not memory function. Non-invasive cancer was not associated with any change in cognitive performance. Patients with prostate cancer had larger frontal brain volumes (Beta = 4.13, p = 0.03). Cancer history was not associated with any other MRI measure.Conclusions: We did not find any strong evidence linking cancer to cognitive or neuroimaging biomarkers that would explain a lower risk of subsequent AD, although a previous FHS study demonstrated a strong inverse association between cancer and risk of AD. Future work should examine the association between cancer and other biomarkers of AD as well as more sensitive metrics of AD-related brain aging markers.
KeyWord	Alzheimer’s disease; cognitive aging; cancer; MRI; neuropsychological assessment
基金项目
页码	-

参考文献
相关文献

1.Tabarés-Seisdedos R, Rubenstein JL. Inverse cancer comorbidity: a serendipitous opportunity to gain insight into CNS disorders. Nat Rev Neurosci. 2013;14(4):293-304. doi: 10.1038/nrn3464

2.Catalá-López F, Suárez-Pinilla M, Suárez-Pinilla P, Valderas JM, Gómez-Beneyto M, Martinez S, et al. Inverse and direct cancer comorbidity in people with central nervous system disorders: a meta-analysis of cancer incidence in 577,013 participants of 50 observational studies. Psychother Psychosom. 2014;83(2):89-105. doi: 10.1159/000356498

3.Roe CM, Fitzpatrick AL, Xiong C, Sieh W, Kuller L, Miller JP, et al. Cancer linked to Alzheimer disease but not vascular dementia. Neurology. 2010;74(2):106-12. doi: 10.1212/WNL.0b013e3181c91873

4.Roe CM, Behrens MI, Xiong C, Miller JP, Morris JC. Alzheimer disease and cancer. Neurology. 2005;64(5):895-8. doi: 10.1212/01.WNL.0000152889.94785.51

5.Musicco M, Adorni F, Di Santo S, Prinelli F, Pettenati C, Caltagirone C, et al. Inverse occurrence of cancer and Alzheimer disease: a population-based incidence study. Neurology. 2013;81(4):322-8. doi: 10.1212/WNL.0b013e31829c5ec1

6.Ou SM, Lee YJ, Hu YW, Liu CJ, Chen TJ, Fuh JL, et al. Does Alzheimer’s disease protect against cancers? A nationwide population-based study. Neuroepidemiology. 2013;40(1):42-9. doi: 10.1159/000341411

7.Romero JP, Benito-León J, Louis ED, Bermejo-Pareja F. Alzheimer’s disease is associated with decreased risk of cancer-specific mortality: a prospective study (NEDICES). J Alzheimers Dis. 2014;40(2):465-73. doi: 10.3233/JAD-132048

8.Driver JA, Beiser A, Au R, Kreger BE, Splansky GL, Kurth T, et al. Inverse association between cancer and Alzheimer’s disease: results from the Framingham Heart Study. BMJ. 2012;344:e1442. doi: 10.1136/bmj.e1442

9.Catalá-López F, Crespo-Facorro B, Vieta E, Valderas JM, Valencia A, Tabarés-Seisdedos R. Alzheimer’s disease and cancer: current epidemiological evidence for a mutual protection. Neuroepidemiology. 2014;42(2):121-2. doi: 10.1159/000355899

10.Zhang Q, Guo S, Zhang X, Tang S, Shao W, Han X, et al. Inverse relationship between cancer and Alzheimer’s disease: a systemic review meta-analysis. Neurol Sci. 2015;36(11):1987-94. doi: 10.1007/s10072-015-2282-2

11.Ibáñez K, Boullosa C, Tabarés-Seisdedos R, Baudot A, Valencia A. Molecular evidence for the inverse comorbidity between central nervous system disorders and cancers detected by transcriptomic meta-analyses. PLoS Genet. 2014;10(2):e1004173. doi: 10.1371/journal.pgen.1004173

12.Ganguli M. Cancer and dementia: it’s complicated. Alzheimer Dis Assoc Disord. 2015;29(2):177-82. doi: 10.1097/WAD.0000000000000086

13.Hanson HA, Horn KP, Rasmussen KM, Hoffman JM, Smith KR. Is cancer protective for subsequent Alzheimer’s disease risk? Evidence from the Utah population database. J Gerontol B Psychol Sci Soc Sci. 2017;72(6):1032-43. doi: 10.1093/geronb/gbw040

14.Ahles TA, Root JC, Ryan EL. Cancer- and cancer treatment-associated cognitive change: an update on the state of the science. J Clin Oncol. 2012;30(30):3675-86. doi: 10.1200/JCO.2012.43.0116

15.McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Alterations in brain activation during working memory processing associated with breast cancer and treatment: a prospective functional magnetic resonance imaging study. J Clin Oncol. 2012;30(20):2500-8. doi: 10.1200/JCO.2011.38.5674

16.De Ruiter MB, Reneman L, Boogerd W, Veltman DJ, Caan M, Douaud G, et al. Late effects of high-dose adjuvant chemotherapy on white and gray matter in breast cancer survivors: converging results from multimodal magnetic resonance imaging. Hum Brain Mapp. 2012;33(12):2971-83. doi: 10.1002/hbm.21422

17.Elias MF, Beiser A, Wolf PA, Au R, White RF, D’Agostino RB. The preclinical phase of alzheimer disease: a 22-year prospective study of the Framingham Cohort. Arch Neurol. 2000;57(6):808-13. doi: 10.1001/archneur.57.6.808

18.Jack CR, Shiung MM, Weigand SD, O’Brien PC, Gunter JL, Boeve BF, et al. Brain atrophy rates predict subsequent clinical conversion in normal elderly and amnestic MCI. Neurology. 2005;65(8):1227-31. doi: 10.1212/01.wnl.0000180958.22678.91

19.Kuller LH, Lopez OL, Newman A, Beauchamp NJ, Burke G, Dulberg C, et al. Risk factors for dementia in the cardiovascular health cognition study. Neuroepidemiology. 2003;22(1):13-22. doi: 10.1159/000067109

20.Prins ND, van Dijk EJ, den Heijer T, Vermeer SE, Koudstaal PJ, Oudkerk M, et al. Cerebral white matter lesions and the risk of dementia. Arch Neurol. 2004;61(10):1531-4. doi: 10.1001/archneur.61.10.1531

21.Benito-León J, Romero JP, Louis ED, Bermejo-Pareja F. Faster cognitive decline in elders without dementia and decreased risk of cancer mortality: NEDICES Study. Neurology. 2014;82(16):1441-8. doi: 10.1212/WNL.0000000000000350

22.Heflin LH, Meyerowitz BE, Hall P, Lichtenstein P, Johansson B, Pedersen NL, et al. Cancer as a risk factor for long-term cognitive deficits and dementia. J Natl Cancer Inst. 2005;97(11):854-6. doi: 10.1093/jnci/dji137

23.Nudelman KNH, Risacher SL, West JD, McDonald BC, Gao S, Saykin AJ, et al. Association of cancer history with Alzheimer’s disease onset and structural brain changes. Front Physiol. 2014;5:423. doi: 10.3389/fphys.2014.00423

24.Feinleib M, Kannel WB, Garrison RJ, McNamara PM, Castelli WP. The Framingham Offspring Study. Design and preliminary data. Prev Med. 1975;4(4):518-25. doi: 10.1016/0091-7435(75)90037-7

25.Kreger BE, Splansky GL, Schatzkin A. The cancer experience in the Framingham Heart Study cohort. Cancer. 1991;67(1):1-6. doi: 10.1002/1097-0142(19910101)67:1<1::AID-CNCR2820670102>3.0.CO;2-W

26.Au R, Seshadri S, Wolf PA, Elias M, Elias P, Sullivan L, et al. New norms for a new generation: cognitive performance in the framingham offspring cohort. Exp Aging Res. 2004;30(4):333-58. doi: 10.1080/03610730490484380

27.DeCarli C, Massaro J, Harvey D, Hald J, Tullberg M, Au R, et al. Measures of brain morphology and infarction in the framingham heart study: establishing what is normal. Neurobiol Aging. 2005;26(4):491-510. doi: 10.1016/j.neurobiolaging.2004.05.004

28.DeCarli C, Murphy DG, Tranh M, Grady CL, Haxby JV, Gillette JA, et al. The effect of white matter hyperintensity volume on brain structure, cognitive performance, and cerebral metabolism of glucose in 51 healthy adults. Neurology. 1995;45(11):2077-84. doi: 10.1212/wnl.45.11.2077

29.DeCarli C, Maisog J, Murphy DG, Teichberg D, Rapoport SI, Horwitz B. Method for quantification of brain, ventricular, and subarachnoid CSF volumes from MR images. J Comput Assist Tomogr. 1992;16(2):274-84.

30.Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer’s disease and other disorders. Nat Rev Neurosci. 2011;12(12):723-38. doi: 10.1038/nrn3114

31.Driver JA. Inverse association between cancer and neurodegenerative disease: review of the epidemiologic and biological evidence. Biogerontology. 2014;15(6):547-57. doi: 10.1007/s10522-014-9523-2

32.Tabarés-Seisdedos R, Dumont N, Baudot A, Valderas JM, Climent J, Valencia A, et al. No paradox, no progress: inverse cancer comorbidity in people with other complex diseases. Lancet Oncol. 2011;12(6):604-8. doi: 10.1016/S1470-2045(11)70041-9

33.Behrens MI, Lendon C, Roe CM. A common biological mechanism in cancer and Alzheimer’s disease? Curr Alzheimer Res. 2009;6(3):196-204. doi: 10.2174/156720509788486608

34.Driver JA, Lu KP. Pin1: a new genetic link between Alzheimer’s disease, cancer and aging. Curr Aging Sci. 2010;3(3):158-65. doi: 10.2174/1874609811003030158

35.Driver JA, Zhou XZ, Lu KP. Pin1 dysregulation helps to explain the inverse association between cancer and Alzheimer’s disease. Biochim Biophys Acta. 2015;1850(10):2069-76. doi: 10.1016/j.bbagen.2014.12.025

36.Demetrius LA, Driver J. Alzheimer’s as a metabolic disease. Biogerontology. 2013;14(6):641-9. doi: 10.1007/s10522-013-9479-7

37.Wefel JS, Lenzi R, Theriault RL, Davis RN, Meyers CA. The cognitive sequelae of standard-dose adjuvant chemotherapy in women with breast carcinoma: results of a prospective, randomized, longitudinal trial. Cancer. 2004;100(11):2292-9. doi: 10.1002/cncr.20272

38.McDonald BC, Conroy SK, Ahles TA, West JD, Saykin AJ. Gray matter reduction associated with systemic chemotherapy for breast cancer: a prospective MRI study. Breast Cancer Res Treat. 2010;123(3):819-28. doi: 10.1007/s10549-010-1088-4

39.Scherling C, Collins B, MacKenzie J, Bielajew C, Smith A. Prechemotherapy differences in response inhibition in breast cancer patients compared to controls: A functional magnetic resonance imaging study. J Clin Exp Neuropsychol. 2012;34(5):543-60. doi: 10.1080/13803395.2012.666227

40.De Ruiter MB, Reneman L, Boogerd W, Veltman DJ, van Dam FS, Nederveen AJ, et al. Cerebral hyporesponsiveness and cognitive impairment 10 years after chemotherapy for breast cancer. Hum Brain Mapp. 2011;32(8):1206-19. doi: 10.1002/hbm.21102

41.Kesler SR, Kent JS, O’Hara R. Prefrontal cortex and executive function impairments in primary breast cancer. Arch Neurol. 2011;68(11):1447-53. doi: 10.1001/archneurol.2011.245

42.Lee PE, Tierney MC, Wu W, Pritchard KI, Rochon PA. Endocrine treatment-associated cognitive impairment in breast cancer survivors: evidence from published studies. Breast Cancer Res Treat. 2016;158(3):407-20. doi: 10.1007/s10549-016-3906-9

引用本文

Apar Gupta,Sarah R. Preis,Alexa S. Beiser,Greta L. Splansky,Charles S. DeCarli,Rhoda Au,Jane A. Driver*. Relationship of Cancer to Brain Aging Markers of Alzheimer’s Disease: The Framingham Heart Study, Advances in Geriatric Medicine and Research. 2019; 1; (1). https://doi.org/10.20900/agmr20190006.

文献评论

相关学者

相关机构